earnings
confidence high
sentiment positive
materiality 0.80
Fortress Biotech posts Q2 net income $13.4M; Checkpoint acquisition yields $28M upfront
Fortress Biotech, Inc.
2025-Q2 EPS reported
$0.02
revenue$29,552,000
- Checkpoint acquired by Sun Pharma in May; Fortress received ~$28M at close, up to $4.8M CVR, plus 2.5% royalty on UNLOXCYT sales.
- FDA accepted CUTX-101 NDA for priority review; PDUFA goal date September 30, 2025.
- Q2 consolidated net revenue $16.4M ($15.0M from dermatology); net income $13.4M vs net loss $13.3M a year ago.
- Consolidated cash $74.4M as of June 30, up from $57.3M at Dec 31, 2024, boosted by Checkpoint proceeds.
- Emrosi commercial launch underway; payer coverage expanded to 100M U.S. commercial lives as of July 2025.